TY - JOUR
AU1 - Hopfinger, Georg
AB - Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.
TI - Hematopoietic stem cell transplantation: up-date from ASH 2016
JF - memo - Magazine of European Medical Oncology
DO - 10.1007/s12254-017-0337-1
DA - 2017-06-01
UR - https://www.deepdyve.com/lp/springer-journals/hematopoietic-stem-cell-transplantation-up-date-from-ash-2016-l0wY5c2AWB
SP - 62
EP - 65
VL - 10
IS - 2
DP - DeepDyve
ER -